Universitätsklinik für Psychiatrie und Psychotherapie Tübingen, Geriatrisches Zentrum am Universitätsklinikum Tübingen, Germany.
Dtsch Arztebl Int. 2010 Oct;107(39):677-83. doi: 10.3238/arztebl.2010.0677. Epub 2010 Oct 1.
The terms "dementia" and "Alzheimer's disease" are often wrongly used as if they were synonyms. Dementia is a clinical syndrome whose main element is memory impairment; it is due to Alzheimer's disease in more than 75% of cases. Alzheimer's disease, on the other hand, is a neuropathological entity that is characterized by a protracted preclinical phase followed by the onset of slowly progressive dementia.
We here review relevant literature that we retrieved by a selective Medline search (2005-2009), paying special attention to the early diagnosis of Alzheimer's disease, its clinical manifestations, and its relevance in primary care.
The early clinical manifestations of a dementing illness can be detected in primary care through the use of simple screening tests such as the mini mental state examination, clock drawing tests, and DemTect. A diminished concentration of Abeta-peptide and an increase of (phospho-)tau in the cerebrospinal fluid can suggest the presence of Alzheimer's disease even before the onset of dementia: these substances are components of amyloid plaques and neurofibrillary tangles, which are the characteristic neuropathological lesions of Alzheimer's disease. New types of morphological magnetic resonsance imaging (MRI), and automated analysis of the images obtained, can improve the consistency of radiological assessment over the traditional visual method and thus enable more secure diagnosis.
The early, preclinical phase of Alzheimer's disease involves what has been termed mild cognitive impairment and may last as long as five years until the onset of dementia. With the aid of the new biomarkers described here, the likelihood of diagnosing Alzheimer's disease correctly in this phase can be raised above 80%. Early detection of Alzheimer's disease before the onset of dementia provides an opportunity to study potential approaches for secondary prevention, which are now an object of intense clinical research.
“痴呆”和“阿尔茨海默病”这两个术语经常被错误地当作同义词使用。痴呆是一种以记忆损害为主要特征的临床综合征,超过 75%的病例是由阿尔茨海默病引起的。另一方面,阿尔茨海默病是一种神经病理学实体,其特征是存在一个漫长的临床前期,随后出现缓慢进展的痴呆。
我们在这里对通过选择性 Medline 搜索(2005-2009 年)获得的相关文献进行了综述,特别关注阿尔茨海默病的早期诊断、临床表现及其在初级保健中的相关性。
通过使用简单的筛查测试,如迷你精神状态检查、画钟测试和 DemTect,在初级保健中可以检测到痴呆性疾病的早期临床症状。脑脊液中 Abeta-肽浓度降低和(磷酸化)tau 增加提示存在阿尔茨海默病,甚至在痴呆发生之前:这些物质是淀粉样斑块和神经原纤维缠结的组成部分,这是阿尔茨海默病的特征性神经病理学病变。新型形态磁共振成像(MRI)以及对获得的图像进行自动分析,可以提高放射学评估的一致性,从而更可靠地进行诊断。
阿尔茨海默病的早期、临床前期涉及到所谓的轻度认知障碍,可能会持续长达五年,直到痴呆的发生。借助这里描述的新生物标志物,可以将在该阶段正确诊断阿尔茨海默病的可能性提高到 80%以上。在痴呆发生之前早期发现阿尔茨海默病为研究潜在的二级预防方法提供了机会,目前这是临床研究的一个热点。